Breast Cancer Symposium

BCS 2013 Daily News Saturday

Issue link:

Contents of this Issue


Page 0 of 11

S AT U R D AY, S E P T E M B E R 7 , 2 0 1 3 | I S S U E 1 | S A N F R A N C I S C O , C A 2013 Breast Cancer Symposium Highlights Multidisciplinary Collaboration, Features New Track for Early-Career Oncologists T he 2013 Breast Cancer Symposium expands on successful features from previous years, with the aim of maximizing interaction with experts. This year's tagline, "Multidisciplinary Perspectives on Clinical Management," highlights the meeting's ongoing focus on collaboration. "The goal of the Symposium is to keep the members of the various specialties abreast of new data and ongoing controversies from other specialties," explained William M. Sikov, MD, of Warren Alpert Medical School of Brown University, and Co-Chair of this year's Program Committee. As always, the Symposium provides an opportunity for members of the oncology community to discuss major INSIDE THIS ISSUE ASBrS to Launch Online Breast Education Self-Assessment Program 3 Expert Editorial: Overdiagnosis in Breast Cancer Screening 4 Find More ASCO CME Opportunities 4 About the 2013 Breast Cancer Symposium Cosponsors This year's Symposium also introduces a new track for fellows, residents, and junior faculty. Meena S. Moran, MD, of Yale University School of Medicine, serves as Chair of this new track and will lead a Networking Reception that provides an opportunity for fellows to gather informally with men- 4 Navigating the Symposium Spotlight on Early-Career Oncologists 5 The General Poster Session provides ample opportunities for professional networking and collaboration. tors. The Networking Reception will be held today, 5:00 PM-6:00 PM (PDT) in Yerba Buena Ballroom, Salon 6. (For more on Dr. Moran's perspective as a radiation oncologist specializing in breast cancer, read the article on page 5.) The track also includes a Best of Journals–Literature Review, geared toward sharing critical reading tips that are See Symposium Highlights Collaboration, Page 2 2 Five Tips for Navigating a General Poster Session developments in breast cancer treatment and applied research in a small, easy to navigate setting. The Symposium is tailored toward both the clinical and research interests of specialists from many disciplines—including medical oncology, surgical oncology, radiation oncology, radiology, reconstructive surgery, and pathology—to focus on the importance of understanding and incorporating the latest research to strengthen collaborative treatment approaches and, ultimately, to enhance patient care. From Where I Sit: A Radiologist's Perspective 5 SSO Receives Komen Grant for Joint Breast Cancer Consensus Statement 6 Expert Editorial: Breast Cancer Biomarkers Beyond Molecular Classification 7 Helpful Tips for Poster Presenters 7 From Where I Sit: A Surgeon's Perspective 8 Skill Validation for Breast Health Care Professionals and Breast Health Care Facilities 8 Visit the Attendee Resource Center Online for Key Symposium Materials 8 Exhibitor Directory 9 ASBD Supports a Multidisciplinary Approach to Breast Cancer Care 10 Why Bother Offering That Clinical Trial? An Internal Dialogue William M. Sikov, MD, FACP Expert Editorial Y ou've completed your patient's history and physical and have stepped out of the room to let her get dressed while preparing to sit down with her and her partner to discuss her diagnosis, stage, prognosis, and treatment recommendations. With their permission, a 2nd-year medical resident will sit in on this discussion. As you wait, you run through what you're planning to say—especially about her standard treatment options and about a clinical trial for which she appears to be eligible: a randomized study that should answer important questions about the treatment of her disease. You know that this part of the conversation can be disconcerting for patients; she was referred to you because of your knowledge and experience, not to have such an important decision made by a computer, by a flip of a virtual coin. Why bother? Why open that can of worms? You're already 40 minutes behind schedule, and the study discussion is bound to add at least a half hour to this visit. It's certainly not for the money; with the exception of a few well-funded pharmaceutical company-sponsored trials, your protocol office actually loses money on a per accrual basis. It's not for the "glory"—there's no way you'll enroll enough patients on this national study to be a named author when the results are Dr. William M. Sikov published, and in the academic scheme of things clinical research is a poor relation. You know the statistics, which you share with the resident—how few patients are candidates for available trials despite efforts to streamline eligibility criteria, how few are offered the chance to be part of a trial, and how few agree to participate—less TARG E T I NG C A NC E R C A RE than 5% of adult patients with cancer enroll on clinical trials, in contrast to more than 60% of children with cancer.1 Challenging Accrual Numbers Too many seemingly well-designed studies fail to meet their accrual goals; in the past, up to 40% of National Cancer Institute (NCI)-sponsored trials failed to complete accrual, although recent data suggest that that percentage should fall going forward, at least for the most vital phase III studies.2 How do you explain to a patient who agreed to participate in a study that the questions it was supposed to address won't be answered because the study wasn't completed? Fortunately, that same analysis projected that only 2% of adult patients with cancer enrolled on ongoing phase III studies will be entered onto studies that will close as a result of inadequate accrual.2 Even so, many trials that eventually fully accrue take much longer than planned to do so. How many axillae were unnecessarily dissected because enrollment to ACOSOG Z0011 was so slow? See Clinical Trials, Page 6

Articles in this issue

Archives of this issue

view archives of Breast Cancer Symposium - BCS 2013 Daily News Saturday